Wall Street Analysts Predict 28.02% Surge for CareDx (CDNA): Trading Strategies Explained
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Should l Buy CDNA?
Source: NASDAQ.COM
Stock Performance and Price Targets: CareDx (CDNA) has seen a 24.7% increase in stock price over the past month, with a mean price target of $22.8 suggesting a potential 28% upside, although estimates vary significantly among analysts.
Analyst Skepticism: Investors should approach price targets with caution, as analysts often set overly optimistic targets influenced by business relationships, and empirical research indicates that these targets can mislead rather than guide investment decisions.
Earnings Estimates and Analyst Consensus: There is growing optimism regarding CareDx's earnings, with recent upward revisions in EPS estimates, leading to a 38.8% increase in the Zacks Consensus Estimate, which may indicate potential stock upside.
Investment Strategy Considerations: While price targets can provide some insight, they should not be the sole basis for investment decisions; a comprehensive analysis of fundamental factors is essential for better ROI.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDNA
Wall Street analysts forecast CDNA stock price to fall
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 19.100
Low
18.00
Averages
18.00
High
18.00
Current: 19.100
Low
18.00
Averages
18.00
High
18.00
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CareDx to Host Investor Webcast on February 12
- Clinical Validation Data Release: CareDx will present pivotal clinical validation data from the ACROBAT study at the 2026 Tandem Meetings, evaluating the effectiveness of its AI-powered AlloHeme test in monitoring relapse in hematologic malignancy patients, potentially enabling timely clinical interventions.
- Investor Webcast Schedule: The company will host an investor webcast on February 12, 2025, to discuss the findings of the ACROBAT study and the commercial launch timeline for AlloHeme, which is expected to attract investor interest in its market potential.
- Study Center Coverage: The ACROBAT study is conducted at 11 hematopoietic stem cell transplant centers across the U.S., involving patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes, showcasing AlloHeme's potential for early cancer relapse detection, which could transform existing monitoring methods.
- Future Outlook: CareDx is committed to improving outcomes for transplant patients through non-invasive molecular testing and digital health technologies, and the successful launch of AlloHeme will further solidify its leadership position in precision medicine, driving long-term growth for the company.
See More
CareDx CEO Sells Nearly 20,000 Shares in Open Market Transactions
- Insider Selling Activity: CareDx CEO John Walter Hanna Jr. sold 19,480 shares on January 21 and 22, 2026, for approximately $412,200, reducing his direct ownership to 96.84%, indicating a strategic decision to liquidate part of his stake.
- Transaction Context: This sale was executed under a Rule 10b5-1 plan, with Hanna Jr. having sold another 10,156 shares a week earlier, suggesting that these transactions were pre-planned and may not significantly influence investor decisions regarding stock purchases.
- Company Financial Performance: CareDx reported preliminary Q4 FY 2025 revenue of $108 million on January 12, 2026, marking a 25% year-over-year increase and surpassing analyst expectations, highlighting the strong growth potential of its testing services.
- Future Growth Outlook: Despite a lackluster performance in 2025, CareDx's stock rose approximately 9% in January 2026, but to realize long-term investment potential, the company must deliver robust results from its AlloSure Kidney and AlloMap Heart testing solutions.
See More
CareDx CEO Sells Shares, Reduces Holdings by 3.16%
- Executive Sell-off: CareDx's President and CEO, John Walter Hanna Jr., sold 19,480 shares on January 21 and 22, 2026, totaling approximately $412,200 at an average price of $21.16 per share, reducing his direct holdings by 3.16% to 597,405 shares, indicating a cautious outlook on the company's future.
- Transaction Plan Context: The stock sale was executed under a Rule 10b5-1 plan, suggesting that these transactions were pre-planned; however, such sell-offs should not deter investors from purchasing the stock, reflecting executive confidence in the market.
- Financial Performance Highlights: CareDx announced preliminary Q4 results for FY 2025 on January 12, 2026, reporting revenue of $108 million, a 25% year-over-year increase, surpassing analyst expectations and showcasing strong growth potential in its testing services.
- Future Growth Expectations: The company anticipates continued robust revenue growth throughout 2026, particularly from its AlloSure Kidney and AlloMap Heart testing services; despite a lackluster performance in 2025, the stock rose approximately 9% in January, indicating optimistic market sentiment regarding its future performance.
See More
CareDx CEO Sells Nearly 20,000 Shares in Open Market Transactions
- Insider Selling Activity: CareDx CEO John Hanna sold 19,480 shares in multiple open-market transactions on January 21 and 22, 2026, with a total transaction value of approximately $412,200, marking the largest of his recent sell-only trades and indicating a need for liquidity.
- Ownership Impact: This transaction reduced Hanna's direct holdings by 3.16%, leaving him with 597,405 shares, which still represents a significant ownership stake, suggesting continued confidence in the company's future despite the reduction.
- Financial Performance Highlights: CareDx reported approximately $108 million in Q4 revenue, a 25% year-over-year increase, and full-year revenue of about $380 million, reflecting a 14% growth, showcasing strong growth potential in the transplant solutions sector despite a 9.36% decline in stock price over the past year.
- Strategic Collaboration Outlook: CareDx has established a strategic collaboration with 10x Genomics to initiate the ImmuneScape research project, focusing on the biology of transplant organ rejection, which will enhance its technological edge in transplant monitoring and clinical diagnostic development.
See More
CareDx (CDNA) Reports Q4 Revenue of $108 Million, Up 25% YoY
- Significant Revenue Growth: CareDx reported preliminary Q4 revenue of approximately $108 million, reflecting a 25% year-over-year increase, indicating strong market performance that is likely to boost investor confidence.
- Testing Services Revenue Rise: Testing services revenue reached approximately $78 million, up 23% year-over-year, demonstrating ongoing growth in the company's core business and enhancing its competitive position.
- Increase in Testing Volume: The volume of testing services approximated 53,000, marking a 17% increase, which reflects rising customer demand and could drive future revenue growth.
- Optimistic 2025 Outlook: Preliminary projections for 2025 revenue stand at approximately $380 million, a 14% year-over-year increase, showcasing the company's confidence in future growth, particularly in the expansion of testing services.
See More
Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.
- Investor Sentiment: January is typically a time of optimism for investors, reflecting a hopeful outlook for the year ahead.
- Corporate Challenges: Despite investor optimism, corporate America may face significant challenges that could impact performance and growth.
See More
CareDx to Host Investor Webcast on February 12
- Clinical Validation Data Release: CareDx will present pivotal clinical validation data from the ACROBAT study at the 2026 Tandem Meetings, evaluating the effectiveness of its AI-powered AlloHeme test in monitoring relapse in hematologic malignancy patients, potentially enabling timely clinical interventions.
- Investor Webcast Schedule: The company will host an investor webcast on February 12, 2025, to discuss the findings of the ACROBAT study and the commercial launch timeline for AlloHeme, which is expected to attract investor interest in its market potential.
- Study Center Coverage: The ACROBAT study is conducted at 11 hematopoietic stem cell transplant centers across the U.S., involving patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes, showcasing AlloHeme's potential for early cancer relapse detection, which could transform existing monitoring methods.
- Future Outlook: CareDx is committed to improving outcomes for transplant patients through non-invasive molecular testing and digital health technologies, and the successful launch of AlloHeme will further solidify its leadership position in precision medicine, driving long-term growth for the company.
See More
CareDx CEO Sells Nearly 20,000 Shares in Open Market Transactions
- Insider Selling Activity: CareDx CEO John Walter Hanna Jr. sold 19,480 shares on January 21 and 22, 2026, for approximately $412,200, reducing his direct ownership to 96.84%, indicating a strategic decision to liquidate part of his stake.
- Transaction Context: This sale was executed under a Rule 10b5-1 plan, with Hanna Jr. having sold another 10,156 shares a week earlier, suggesting that these transactions were pre-planned and may not significantly influence investor decisions regarding stock purchases.
- Company Financial Performance: CareDx reported preliminary Q4 FY 2025 revenue of $108 million on January 12, 2026, marking a 25% year-over-year increase and surpassing analyst expectations, highlighting the strong growth potential of its testing services.
- Future Growth Outlook: Despite a lackluster performance in 2025, CareDx's stock rose approximately 9% in January 2026, but to realize long-term investment potential, the company must deliver robust results from its AlloSure Kidney and AlloMap Heart testing solutions.
See More
CareDx CEO Sells Shares, Reduces Holdings by 3.16%
- Executive Sell-off: CareDx's President and CEO, John Walter Hanna Jr., sold 19,480 shares on January 21 and 22, 2026, totaling approximately $412,200 at an average price of $21.16 per share, reducing his direct holdings by 3.16% to 597,405 shares, indicating a cautious outlook on the company's future.
- Transaction Plan Context: The stock sale was executed under a Rule 10b5-1 plan, suggesting that these transactions were pre-planned; however, such sell-offs should not deter investors from purchasing the stock, reflecting executive confidence in the market.
- Financial Performance Highlights: CareDx announced preliminary Q4 results for FY 2025 on January 12, 2026, reporting revenue of $108 million, a 25% year-over-year increase, surpassing analyst expectations and showcasing strong growth potential in its testing services.
- Future Growth Expectations: The company anticipates continued robust revenue growth throughout 2026, particularly from its AlloSure Kidney and AlloMap Heart testing services; despite a lackluster performance in 2025, the stock rose approximately 9% in January, indicating optimistic market sentiment regarding its future performance.
See More
CareDx CEO Sells Nearly 20,000 Shares in Open Market Transactions
- Insider Selling Activity: CareDx CEO John Hanna sold 19,480 shares in multiple open-market transactions on January 21 and 22, 2026, with a total transaction value of approximately $412,200, marking the largest of his recent sell-only trades and indicating a need for liquidity.
- Ownership Impact: This transaction reduced Hanna's direct holdings by 3.16%, leaving him with 597,405 shares, which still represents a significant ownership stake, suggesting continued confidence in the company's future despite the reduction.
- Financial Performance Highlights: CareDx reported approximately $108 million in Q4 revenue, a 25% year-over-year increase, and full-year revenue of about $380 million, reflecting a 14% growth, showcasing strong growth potential in the transplant solutions sector despite a 9.36% decline in stock price over the past year.
- Strategic Collaboration Outlook: CareDx has established a strategic collaboration with 10x Genomics to initiate the ImmuneScape research project, focusing on the biology of transplant organ rejection, which will enhance its technological edge in transplant monitoring and clinical diagnostic development.
See More
CareDx (CDNA) Reports Q4 Revenue of $108 Million, Up 25% YoY
- Significant Revenue Growth: CareDx reported preliminary Q4 revenue of approximately $108 million, reflecting a 25% year-over-year increase, indicating strong market performance that is likely to boost investor confidence.
- Testing Services Revenue Rise: Testing services revenue reached approximately $78 million, up 23% year-over-year, demonstrating ongoing growth in the company's core business and enhancing its competitive position.
- Increase in Testing Volume: The volume of testing services approximated 53,000, marking a 17% increase, which reflects rising customer demand and could drive future revenue growth.
- Optimistic 2025 Outlook: Preliminary projections for 2025 revenue stand at approximately $380 million, a 14% year-over-year increase, showcasing the company's confidence in future growth, particularly in the expansion of testing services.
See More
Earnings Warning Season is Here: Strategies to Benefit from Others' Struggles.
- Investor Sentiment: January is typically a time of optimism for investors, reflecting a hopeful outlook for the year ahead.
- Corporate Challenges: Despite investor optimism, corporate America may face significant challenges that could impact performance and growth.
See More
